202 related articles for article (PubMed ID: 7508533)
1. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression.
Reuss-Borst MA; Bühring HJ; Schmidt H; Müller CA
Leukemia; 1994 Feb; 8(2):258-63. PubMed ID: 7508533
[TBL] [Abstract][Full Text] [Related]
2. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells.
Bühring HJ; Ullrich A; Schaudt K; Müller CA; Busch FW
Leukemia; 1991 Oct; 5(10):854-60. PubMed ID: 1720490
[TBL] [Abstract][Full Text] [Related]
3. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
4. Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor.
Ikeda H; Kanakura Y; Furitsu T; Kitayama H; Sugahara H; Nishiura T; Karasuno T; Tomiyama Y; Yamatodani A; Kanayama Y
Exp Hematol; 1993 Dec; 21(13):1686-94. PubMed ID: 7694869
[TBL] [Abstract][Full Text] [Related]
5. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.
Siitonen T; Savolainen ER; Koistinen P
Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping and functional studies with three monoclonal antibodies to the c-kit receptor tyrosine kinase, YB5.B8, 17F11, and SR-1.
Ashman LK; Bühring HJ; Aylett GW; Broudy VC; Müller C
J Cell Physiol; 1994 Mar; 158(3):545-54. PubMed ID: 7510297
[TBL] [Abstract][Full Text] [Related]
7. The c-kit molecule and the surface immunophenotype of human acute leukemia.
Kubota A; Okamura S; Shimoda K; Harada M; Niho Y
Leuk Lymphoma; 1994 Aug; 14(5-6):421-8. PubMed ID: 7529077
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of erythroid differentiation by stem cell factor in K562 cells expressing the c-kit gene.
Ogawa K; Tashima M; Toi T; Sawai H; Sawada H; Fujita J; Maruyama Y; Okuma M
Exp Hematol; 1994 Jan; 22(1):45-51. PubMed ID: 7506674
[TBL] [Abstract][Full Text] [Related]
9. Mast cell growth factor, a ligand for the receptor encoded by c-kit, affects the growth in culture of the blast cells of acute myeloblastic leukemia.
Wang C; Koistinen P; Yang GS; Williams DE; Lyman SD; Minden MD; McCulloch EA
Leukemia; 1991 Jun; 5(6):493-9. PubMed ID: 1711640
[TBL] [Abstract][Full Text] [Related]
10. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.
Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA
Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644
[TBL] [Abstract][Full Text] [Related]
11. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
12. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-kit receptor (CD117) and CD34 in leukemic cells.
Muroi K; Nakamura M; Amemiya Y; Suda T; Miura Y
Leuk Lymphoma; 1995 Jan; 16(3-4):297-305. PubMed ID: 7536510
[TBL] [Abstract][Full Text] [Related]
14. The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes.
deCastro CM; Denning SM; Langdon S; Vandenbark GR; Kurtzberg J; Scearce R; Haynes BF; Kaufman RE
Exp Hematol; 1994 Sep; 22(10):1025-33. PubMed ID: 7522182
[TBL] [Abstract][Full Text] [Related]
15. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts.
Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W
Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
17. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia.
Lauria F; Bagnara GP; Rondelli D; Raspadori D; Strippoli P; Bonsi L; Ventura MA; Montanaro LL; Bubola G; Tura S
Leuk Lymphoma; 1995 Aug; 18(5-6):451-5. PubMed ID: 8528052
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.
Knapp W; Strobl H; Majdic O
Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675
[TBL] [Abstract][Full Text] [Related]
20. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
